The FDA has approved icotrokinra (Icotyde), the first oral treatment for plaque psoriasis targeting interleukin-23 (IL-23).[1][4] The drug is intended for adults and children from 12 years of age with a moderate to severe form of the disease.[1][2] Johnson & Johnson announced approval based on data from four pivotal Phase 3 studies in the ICONIC program, including ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2.[1][2][3] Icotrokinra met all primary and co-primary endpoints, including IGA score 0/1 (clear or nearly clear skin) and PASI 90 at week 16 versus placebo.[2][3][4] In studies ICONIC-ADVANCE 1 and 2, it demonstrated superiority over deucravacitinib at weeks 16 and 24.[1][2][4] Safety data showed a similar rate of adverse events to placebo (49.1% vs. 51.9%).[1][4] In the long-term ICONIC-TOTAL study, 67% of patients achieved clear or nearly clear skin (IGA 0/1) at week 52.[5] The treatment is given once a day in the form of a tablet.[1][2]